A case report of acute interstitial nephritis caused by cotton phenol

A case report of acute interstitial nephritis caused by cotton phenol | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Case Report A case report of acute interstitial nephritis caused by cotton phenol Ming Zhao, Dongyang Jiang, Pengcheng Zhou, Yinglan Liang, Jian Liu, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5693104/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 19 May, 2025 Read the published version in BMC Urology → Version 1 posted 11 You are reading this latest preprint version Abstract BACKGROUND Cotton phenol is a yellowish-brown polyphenol hydroxybinaphthyl aldehyde compound mainly found in the roots, stems, leaves and seeds of cotton; a plant of the mallow family that has been widely used in the study of antifertility and antitumor drugs. However, there has been no report of serious renal injuries caused by cotton phenol. We report a case of granulomatous acute interstitial nephritis caused by exposure to large amounts of cotton phenol. CASE DESCRIPTION The patient was a 56-year-old male with nausea and a blood creatinine level of 4.95 mg/dL 2 month prior to admission. He was admitted to the hospital with worsening nausea, blood creatinine level of 7.21 mg/dL, and a renal puncture biopsy suggesting granulomatous acute interstitial nephritis. The patient had no specific past medical history. Laboratory tests (double-stranded DNA, antineutrophil cytoplasmic antibody, extractable nuclear antigen, rheumatoid subunit, serum and urine protein electrophoresis, complement levels, immunoglobulin subclasses, streptococcal serology, and hepatitis B and C serology were negative, normal or undetectable. Follow-up history revealed that the patient receives large quantities of cotton phenol at work. The diagnosis was granulomatous acute interstitial nephritis induced by exposure to cotton phenol. Treatment was volume management, maintenance of a stable internal environment, and glucocorticoid activation. Blood creatinine level gradually decreased to 1.86 mg/dL after 3 month and his condition improved. CONCLUSIONS Physicians encountering patients with acute interstitial nephritis of uncertain etiology are obligated to conduct a prompt and comprehensive history review. Special attention should be given to cotton phenol and its derivatives as they may potentially act as nephrotoxic agents. The application of glucocorticoids in the treatment of acute interstitial nephritis remains a subject of debate. However, in this particular case, the patient exhibited a rapid restoration of renal function following the administration of glucocorticoids. case report cotton phenol acute interstitial nephritis glucocorticosteroid Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Introduction Acute interstitial nephritis (AIN) is a tubulointerstitial renal disease characterised by acute inflammation and oedema of the renal interstitium, accompanied by impairment of renal tubular function. It is also known as acute tubulo-interstitial nephritis. The term AIN was first proposed by Councilman in 1898 during the autopsy of a group of patients with diphtheria and scarlet fever. The incidence of AIN varies considerably between different countries and regions. A review of the literature on renal biopsy cases indicates that AIN accounts for 1–2% of cases in many countries[ 1 ]. In patients who have had renal biopsies for acute kidney injury(AKI), AIN accounts for 15–27% of cases[ 2 ]. The most common causes of AIN can be categorised into four groups: exogenous compounds such as drugs, infections, autoimmune disorders, and idiopathic causes (Table 1 ), with drugs being the most prevalent[ 3 ]. All causes of AIN may present with nonspecific signs and symptoms of acute renal insufficiency, including acute or subacute nausea, vomiting, discomfort, oliguria and haematuria. We present a case of severe AKI triggered by exposure to cotton phenol. Percutaneous nephron puncture biopsy confirmed that the patient's renal failure was caused by AIN. The objective of this case report is to emphasise the role of cotton phenol as a rare cause of AIN. Through in-depth analysis of this case, we aim to enhance the understanding of AIN and provide guidance for the diagnosis and management of similar cases in the future. Table 1 Causes of acute interstitial nephritis[ 3 ] Cause of disease Instance Exogenous compounds such as drugs Antibiotics (Penicillins, Cephalosporins, Quinolones, Sulfonamides, Macrolides), anti-retrovirals (Abacavir, Acyclovir, Atazanavir, Azythromycin, Foscarnet, Indinavir, Interferon-alpha), non-steroidal anti-inflammatory drugs (Celecoxib, Rofecoxib, Diclofenac), diuretics (Chlorothiazide, Hydrochlorothiazide), anticonvulsants (Carbamazepine, Diazepam, Lamotrigine, Levetiracetam, Phenobarbital, Phenytoin, Valproic acid), proton pump inhibitors (Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, Rabeprazole), H2 receptor blockers (Cimetidine, Famotidine, Ranitidine), herbs(traditional Chinese herbal medicines containing triptolide, ephedrine, aristolochic acid) Infections Bacteria, viruses, leptospira, mycobacterium tuberculosis, mycoplasma, chlamydia. Autoimmune disease Systemic lupus erythematosus, nodular disease, Sjögren’s syndrome. Idiopathic Anti-renal tubular basement membrane disease, interstitial nephritis–uveitis syndrome. Case report A 56-year-old male patient was admitted to hospital with recurrent nausea, accompanied by elevated blood creatinine for 2 months. Two months ago, he was assessed in the local hospital for nausea and found to have renal insufficiency: urea 15.8 mmol/L, blood creatinine 4.95 mg/dL, and uric acid 9.66 mg/dL. Routine urinalysis revealed urinary protein 1+. Urological ultrasound revealed: right kidney size 9.1 cm × 4.9 cm, left kidney size 10.2 cm × 5.7 cm, and right kidney stone. After treatment with uric acid control (sodium bicarbonate) and volume management in the local hospital, there was no relief of the above symptoms, and he was transferred to our hospital for further consultation. He had no antecedent history of kidney-related disorders. During annual routine physical examinations, no evidence of impaired renal function was identified. Additionally, the patient denied a history of other specific diseases, including hypertension, diabetes mellitus, hepatitis, and tuberculosis. His vital signs were all normal at the time of admission, with no positive findings. The blood routine examination results indicated the presence of mild anemia along with a potential inflammatory state. The serum creatinine level was elevated to 7.21 mg/dL. In the urinalysis, 2 + urinary occult blood was detected; the levels of urinary α₁-microglobulin and urinary microalbumin were abnormally elevated; the result of the 24-hour urinary protein quantification was normal. No abnormalities were found in either the liver function tests or the immunological assays. The chest computed tomography (CT) scan demonstrated scattered inflammatory foci in the lungs and multiple nodules, for which the probability of them being inflammatory nodules was considered to be high. The detailed examination results are presented as follows: Table 2 Patient's preliminary laboratory results Index Results Normal Reference Range for Adult Males Routine blood tests red blood cell count (×10 12 /L) 3.89 * 4.0 ~ 5.5 haemoglobin (g/L) 113 * 120 ~ 160 white blood cell count (×10⁹/L) 4.77 4 ~ 10 neutrophil absolute count (×10⁹/L) 3.48 2 ~ 7 lymphocyte absolute count (×10⁹/L) 0.71 * 0.8 ~ 4.0 high-sensitivity C-reactive protein (mg/L) 9.41 ✝ < 3 platelet count (×10⁹/L) 274 100 ~ 300 erythrocyte sedimentation rate (mm/h) 57 ✝ 0 ~ 20 Liver function albumin (g/L) 38.6 35 ~ 55 globulin (g/L) 31.5 20 ~ 35 total bilirubin (µmol/L) 9 3.4 ~ 17.1 aspartate aminotransferase (U/L) 17 < 40 alanine aminotransferase (U/L) 13 < 40 Kidney function blood urea nitrogen (mmol/L) 21.6 ✝ 2.9 ~ 7.2 blood creatinine (mg/dL) 7.21 ✝ 0.6 ~ 1.2 uric acid (mg/dL) 9.87 ✝ 3.5 ~ 7.2 Electrolytes K (mmol/L) 4.18 3.5 ~ 5.5 Na (mmol/L) 140 135 ~ 145 Cl (mmol/L) 103 96 ~ 106 Ca (mmol/L) 2.29 2.25 ~ 2.58 Pi (mmol/L) 1.45 0.97 ~ 1.61 Mg (mmol/L) 0.9 0.7 ~ 1.10 Routine urinalysis urine potein - - leukocyturi - - occult blood in urine 2+ ✝ - Parathyroid hormone (pg/mL) 20.7 15 ~ 65 urine α₁-microglobulin (mg/L) 227 ✝ 0 ~ 15 urine microalbumin (mg/L) 90.8 ✝ < 30 24-hour urine output (L) 1.8 24-hour urine protein quantification (mg/24H) 129.6 < 150 Autoantibody spectrum nRNP/Sm antibody - - Sm antibody - - Ro-52 antibody - - SS-B antibody - - Scl-70 antibody - - PM-Scl antibody - - Jo-1 antibody - - CENP-B antibody - - PCNA antibody - - dsDNA antibody - - Nucleosome antibody - - Histone - - Ribosomal P protein - - AMA M2 - - anti-MPO antibody - - anti-PR3 antibody - - anti-GBM antibody - - SS-A antibody - - ANA - - Antistreptolysin O (IU/ml) < 25 0 ~ 200 Rheumatoid Factor < 20 0 ~ 20 Complement C3 (g/L) 1.09 0.7 ~ 1.5 C4 (g/L) 0.36 0.1 ~ 0.4 Hepatitis B Five-item Test HBsAg (IU/ml) 0.01 0 ~ 0.5 Anti-HBs (mIU/ml) 0.89 0 ~ 10 HBeAg (IU/ml) 0.01 0 ~ 0.5 Anti-HBe (PEI U/ml) 0.02 0 ~ 0.2 Anti-HBc (PEI U/ml) 0.28 0 ~ 0.9 Hepatitis C Virus Antibody Test (S/CO) 0.01 < 1.0 HIV Antibody Test (S/CO) 0.02 < 1.0 TP Antibody Test (S/CO) 0.02 < 1.0 *: the corresponding value is below the lower limit of the normal reference range; ✝: the corresponding value is above the upper limit of the normal reference range. Chest CT: (1) Nodules in the posterior segment of the upper lobe of the right lung with peripheral inflammatory changes, consider the possibility of infectious lesions, suggest follow-up after treatment; scattered inflammatory changes in both lungs. (2) Multiple solid nodular shadows in both lungs, inflammatory nodules? (3)Multiple mediastinal lymph nodes showing partial calcification; localised pleural calcification in the left lung apex. Renal puncture biopsy: granulomatous interstitial nephritis (Fig. 1–5). No immune complex deposition was observed. 3. Treatment and follow-up 3.1. Days 1–11 after admission : The patient was admitted with a clear AKI, and potential pulmonary infection, and was immediately treated with anti-infection (piperacillin sodium), volume management, maintenance of a stable internal environment, and dietary guidance. We continued to test his vital signs, as well as any fluctuations of his high-sensitivity C-reactive protein (hs-CRP), electrolytes and renal function. The patient's renal function showed a trend of continued progression, and renal puncture biopsy was perfected on day 7 after admission, and the hs-CRP was reduced to normal (2.27 mg/L). Chest CT showed that the pulmonary nodules were reduced. 3.2. From day 11 after admission to discharge : The pathology report of renal biopsy was returned on day 11 after admission. After integrating the patient's auxiliary examination and medical history, we finally diagnosed the patient with cotton-phenol-induced AIN. At that time, the patient's blood creatinine level was already as high as 7.88 mg/dL. He continued to follow the treatment plan for 3 days, and on day 14, blood creatinine level was rechecked as 7.95 mg/dL. In accordance with the patient's wishes, renal replacement therapy was not carried out at that time. So we decided to use glucocorticoids, and after 14 days of intravenous glucocorticoids (40mg/day), the blood creatinine level gradually decreased to 3.30 mg/dL. Symptoms such as nausea gradually disappeared and his appetite gradually improved. The patient was discharged from hospital when his condition improved gradually (Fig. 6). 3.3 Post-discharge follow-up : The patient was discharged on regular glucocorticosteroids (40 mg po daily) and blood creatinine was 2.04 mg/dL 1 month after discharge. Discussion The patient was admitted to the hospital with a definite diagnosis of AKI, but the primary etiology remained unclear. We conducted tests for anti-myeloperoxidase (MPO) antibody, anti-proteinase 3 (PR3) antibody, antinuclear antibody (ANA), double-stranded DNA (dsDNA), and complement levels, all of which showed no abnormalities. Therefore, we ruled out the diagnoses of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, systemic lupus erythematosus nephritis, IgG4-related diseases, and hypocomplementemic AIN. Tests for anti-Ro/SSA and anti-La/SSB antibodies and rheumatoid factor (RF) were also performed, and the results did not support the diagnosis of Sjögren's syndrome. The results of streptococcal serology, as well as serology for hepatitis B and C, were all negative, which was inconsistent with virus-associated nephritis. Although the chest CT scan and hs-CRP indicated the presence of a pulmonary infection, the patient had no respiratory symptoms such as fever or chills, nor any systemic symptoms. The white blood cell count did not increase abnormally. Further improvement of sputum culture did not detect any bacterial or fungal infections. Moreover, after 7 days of anti-infective treatment, a repeated chest CT scan showed that the pulmonary nodules had decreased in size compared with the previous one, and the hs-CRP had dropped to the normal level. In summary, the patient's infection was under control, but the serum creatinine level did not decrease, and the renal function did not improve. Therefore, infectious interstitial nephritis was not considered. All the above common infectious, autoimmune, and idiopathic etiologies were excluded. Further improvement of renal puncture biopsy confirmed that the patient had granulomatous interstitial nephritis. We considered the possibility of AIN caused by sarcoidosis or Mycobacterium tuberculosis infection. We further improved the relevant examinations. Although the patient's T-Cell-based Interferon-Gamma Release Assay (TB-IGRA) result was positive and the chest CT scan also suggested infectious changes, the acid-fast staining of urine sediment and the test for Mycobacterium tuberculosis were both negative. The infectious changes in the lungs did not conform to the typical manifestations of pulmonary tuberculosis. At the same time, the patient had no previous history of tuberculosis, and there were no typical symptoms such as hemoptysis, chest pain, hectic fever, night sweats, or weight loss during hospitalization. In conclusion, the possibility of AIN caused by tuberculosis was extremely low. Although the chest CT scan of the patient suggested multiple nodules, they were considered to be infectious nodules. Meanwhile, the patient's serum calcium level was normal, and no typical manifestations of sarcoidosis were found during physical examination. Therefore, AIN caused by sarcoidosis was also not considered. We carefully inquired about the patient's medical history again. The patient recalled that he had changed his job 5 months ago. His new job mainly involved automotive repair and maintenance. In his daily work, the lubricating oil he used was crude cottonseed oil that he pressed from cottonseeds by himself. This crude cottonseed oil contains a large amount of gossypol[ 4 ]. He came into bare-handed contact with the crude cottonseed oil every day. Moreover, his working environment had poor ventilation, and he worked about 6 hours a day. During work, he neither wore a mask nor gloves. In a follow-up visit after the patient was discharged from the hospital, he stated that his colleagues in the same position as him also had the same impaired renal function. Finally, we diagnosed the patient as having a granulomatous AIN caused by large amounts of cotton phenol exposure. we clarified the final aetiology during a follow-up visit after the patient was discharged, when he stated that his workmates in the same position as him had the same impaired renal function. It has been shown experimentally that cotton phenol can cause renal damage in mice, as demonstrated by diffuse thylakoid cell hyperplasia, increased thylakoid stroma, adhesion to the wall layer of the renal capsule, marked reduction or even disappearance of the renal capsule lumen, disruption of the structural texture, and morphological abnormalities[ 5 ]. Cotton phenol is a polyphenolic compound, with the chemical formula C 30 H 30 O 8 , that occurs naturally in the cotton plant, which can enhance the plant resistance to pests. In terms of medical applications, cotton phenol and its derivatives show a wide range of therapeutic potential. In addition to its properties against some viruses and bacteria[ 6 – 12 ], cotton phenol has been investigated as a potential drug for the treatment of a wide range of malignancies such as leukaemia, lymphoma, colon cancer, breast cancer, leiomyosarcoma and prostate cancer[ 13 – 26 ]. Its mechanism of action involves inhibition of tumour cell proliferation and induction of apoptosis, and these properties have made cotton phenol the subject of much attention in the field of anticancer therapy. In addition, cotton phenol has shown significant value in the treatment of gynaecological conditions, such as uterine fibroids, endometriosis and uterine bleeding. It was introduced into clinical practice in China in the 1970s and continues to be explored for its potential application in the treatment of gynaecological diseases[ 18 ]. Although the application of cotton phenol is promising, its reproductive toxicity has limited its widespread clinical use. Therefore, researchers are endeavouring to find and develop safer and more effective derivatives to further expand its applications. Cotton phenol can also cause toxic effects in animals, mainly through the Browning or Meladic reaction with amino acids, which reduces the absorption and utilisation of amino acids, or by interfering with the activity of enzymes in the electron transport chain of mitochondria (especially dehydrogenases and oxidoreductases) or by directly damaging the mitochondrial membrane. It also affects the mitochondrial membrane potential, leading to mitochondrial dysfunction, thus affecting cellular energy metabolism and inducing toxicity[ 27 – 29 ]. Cotton phenol can also lead to a decrease in the number of leukocytes and major lymphocytes, thus affecting immunity[ 27 ]. Cotton phenol has been reported to cause toxicity in a variety of animals such as cattle, sheep, pigs ,dogs and chickens, which may result in congestion and oedema of internal organs, liver and kidney damage, or cardiac damage[ 30 ]. AIN is an AKI characterised by acute inflammation and oedema of the renal interstitium, accompanied by acute tubular dysfunction. Clinical diagnosis of AIN can usually be made on the basis of the typical history, clinical manifestations and laboratory tests, but renal puncture biopsy is the gold standard for the diagnosis. The usual treatments for AIN are: (1) removal of causative factors, such as, stopping related drugs, and treating primary infection; (2) systemic supportive therapy; and (3) immunosuppressive therapy, including glucocorticoids and immunosuppressive drugs. Timely diagnosis and treatment can avoid disease progression, and some patients can fully recover renal function, whereas others may progress to chronic kidney disease. In conclusion, the causative factors, disease duration, degree of renal function impairment, degree of interstitial fibrosis, and the timeliness and appropriateness of the treatment all affect the prognosis of AIN. The use of glucocorticoids in the treatment of AIN has been controversial. The best evidence in support of glucocorticoid therapy comes from a retrospective multicentre study in Spain, which included 61 patients with biopsy-proven AIN; 52 of whom received glucocorticoid therapy. Despite the small sample size of the control group, with only nine patients who did not receive glucocorticoids, the results showed a positive impact of glucocorticoids on the recovery of renal function and shedding of dialysis at 18-months' follow-up[ 31 ]. Although there have been several small studies with similar results to this study[ 32 ], not all of them have supported the efficacy of glucocorticoids. For example, a retrospective study in 2004 in the USA found that glucocorticoids did not show any therapeutic advantage in 60 patients with biopsy-confirmed drug-induced AIN[ 33 ]. Some negative studies have suggested that the ineffectiveness of glucocorticoid therapy may be related to the inclusion of patients with more severe disease and patients with AIN induced by nonsteroidal anti-inflammatory drugs (where glucocorticoids may be ineffective). However, in the present case, the patient's renal function recovered rapidly after glucocorticoids were activated. This case reminds physicians to consider the possibility of AIN in any diagnosis of unexplained AKI, and the need for timely medical history review and consideration of the patient's environmental exposures when the aetiological diagnosis is more difficult, in order to avoid missed or misdiagnosis, which may delay treatment and affect prognosis. At present, cotton phenol and its derivatives find extensive applications. For instance, they are utilized in the manufacture of anti-fertility drugs, for the prevention and management of pests and diseases in crops[ 34 ], and serve as antioxidants in the rubber industry, polyethylene industry, polypropylene industry, as well as in rocket fuel and so on[ 35 ]. This reminds physicians to consider it as a potential nephrotoxicant when they see patients engaged in the relevant industries. Abbreviations AIN acute interstitial nephritis AKI acute kidney injury ANA antinuclear antibody ANCA antineutrophil cytoplasmic antibody ANCA antineutrophil cytoplasmic antibodies CT computed tomography dsDNA double-stranded DNA hs-CRP high-sensitivity C-reactive protein MPO myeloperoxidase PR3 proteinase 3 Declarations Ethics approval and consent to participate This case report was in adherence with the Declaration of Helsinki and approved by the Ethics Committee of The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, approval number KY2023020-FS01. The authors declared that written informed consent was obtained from the patient for publication of this case report and accompanying images. Consent for publication The article has been read by the patient himself and agreed to be published in ' BMC Urology’. Our patient gave written informed consent for their personal or clinical details along with any identifying images to be published in this study. (The specific written informed consent can be seen in the relevant documents uploaded.) Availability of data and materials The datasets used during the current study are available from the corresponding author on reasonable request. Competing interests The authors declare no competing interests. Funding This research was supported by ‘Luzhou Municipal People's Government-Southwest Medical University Science and Technology Strategic Cooperation Project’, ‘Sichuan Science and Technology Program’, ‘Sichuan Administration of Traditional Chinese Medicine’ and ‘Southwest Medical University - Southwest Medical University affiliated Hospital of Traditional Chinese Medicine joint project’. Authors’ contributions MZ, DJ, PZ, and JL contributed to patient diagnosis, management, and clinical data analysis. MZ, HS, YL and QH contributed to the patient’s pathological diagnosis and took and edited pathological pictures. MZ and DJ wrote the manuscript draft and contributed to data analysis, and interpretation. QZ made final changes to the interpretation of the pathology images in the manuscript and to the content of the manuscript. Acknowledgements Not applicable. References Zhang Q, Chen N: The etiology and pathogenesis of acute interstitial nephritis and progress in its diagnosis and treatment . Chinese Journal of Practical Internal Medicine 2006(06):476-478. Praga M, González E: Acute interstitial nephritis . Kidney Int 2010, 77 (11):956-961. Raghavan R, Eknoyan G: Acute interstitial nephritis - a reappraisal and update . Clin Nephrol 2014, 82 (3):149-162. Qian SZ, Wang ZG: Gossypol: a potential antifertility agent for males . Annu Rev Pharmacol Toxicol 1984, 24 :329-360. Wang H, Piao Z, Ma H, Cao L, Liu J, Wu J: [Short-term exposure to gossypol causes reversible reproductive toxicity and nephrotoxicity in mice] . Nan Fang Yi Ke Da Xue Xue Bao 2023, 43 (2):251-256. Polsky B, Segal SJ, Baron PA, Gold JW, Ueno H, Armstrong D: Inactivation of human immunodeficiency virus in vitro by gossypol . Contraception 1989, 39 (6):579-587. Yang J, Zhang F, Li J, Chen G, Wu S, Ouyang W, Pan W, Yu R, Yang J, Tien P: Synthesis and antiviral activities of novel gossypol derivatives . Bioorg Med Chem Lett 2012, 22 (3):1415-1420. Yang J, Chen G, Li LL, Pan W, Zhang F, Yang J, Wu S, Tien P: Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism . Bioorg Med Chem Lett 2013, 23 (9):2619-2623. Margalith P: Inhibitory effect of gossypol on microorganisms . Appl Microbiol 1967, 15 (4):952-953. Yildirim-Aksoy M, Lim C, Dowd MK, Wan PJ, Klesius PH, Shoemaker C: In vitro inhibitory effect of gossypol from gossypol-acetic acid, and (+)- and (-)-isomers of gossypol on the growth of Edwardsiella ictaluri . J Appl Microbiol 2004, 97 (1):87-92. Turco E, Vizzuso C, Franceschini S, Ragazzi A, Stefanini FM: The in vitro effect of gossypol and its interaction with salts on conidial germination and viability of Fusarium oxysporum sp. vasinfectum isolates . J Appl Microbiol 2007, 103 (6):2370-2381. Arinbasarova AY, Medentsev AG, Krupyanko VI: Gossypol Inhibits Electron Transport and Stimulates ROS Generation in Yarrowia lipolytica Mitochondria . Open Biochem J 2012, 6 :11-15. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V: Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells . Blood 2008, 112 (5):1971-1980. Johnson PW: New targets for lymphoma treatment . Ann Oncol 2008, 19 Suppl 4 :iv56-59. Wang X, Wang J, Wong SC, Chow LS, Nicholls JM, Wong YC, Liu Y, Kwong DL, Sham JS, Tsa SW: Cytotoxic effect of gossypol on colon carcinoma cells . Life Sci 2000, 67 (22):2663-2671. Van Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K, Borgen P, Gollub M, Bacotti D, Yao TJ et al : Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial . Breast Cancer Res Treat 2001, 66 (3):239-248. Ye W, Chang HL, Wang LS, Huang YW, Shu S, Dowd MK, Wan PJ, Sugimoto Y, Lin YC: Modulation of multidrug resistance gene expression in human breast cancer cells by (-)-gossypol-enriched cottonseed oil . Anticancer Res 2007, 27 (1a):107-116. Han ML, Wang YF, Tang MY, Ge QS, Zhou LF, Zhu PD, Sun YT: Gossypol in the treatment of endometriosis and uterine myoma . Contrib Gynecol Obstet 1987, 16 :268-270. Jiang J, Slivova V, Jedinak A, Sliva D: Gossypol inhibits growth, invasiveness, and angiogenesis in human prostate cancer cells by modulating NF-κB/AP-1 dependent- and independent-signaling . Clin Exp Metastasis 2012, 29 (2):165-178. Tuszynski GP, Cossu G: Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines . Cancer Res 1984, 44 (2):768-771. Wu YW, Chik CL, Knazek RA: An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenocortical carcinoma . Cancer Res 1989, 49 (14):3754-3758. Badawy SZ, Souid AK, Cuenca V, Montalto N, Shue F: Gossypol inhibits proliferation of endometrioma cells in culture . Asian J Androl 2007, 9 (3):388-393. Ko CH, Shen SC, Yang LY, Lin CW, Chen YC: Gossypol reduction of tumor growth through ROS-dependent mitochondria pathway in human colorectal carcinoma cells . Int J Cancer 2007, 121 (8):1670-1679. Chien CC, Ko CH, Shen SC, Yang LY, Chen YC: The role of COX-2/PGE2 in gossypol-induced apoptosis of colorectal carcinoma cells . J Cell Physiol 2012, 227 (8):3128-3137. Hsiao WT, Tsai MD, Jow GM, Tien LT, Lee YJ: Involvement of Smac, p53, and caspase pathways in induction of apoptosis by gossypol in human retinoblastoma cells . Mol Vis 2012, 18 :2033-2042. Wong FY, Liem N, Xie C, Yan FL, Wong WC, Wang L, Yong WP: Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression . PLoS One 2012, 7 (12):e50786. Meksongsee LA, Clawson AJ, Smith FH: The in vivo effect of gossypol on cytochrome oxidase, succinoxidase, and succinic dehydrogenase in animal tissues . J Agric Food Chem 1970, 18 (5):917-920. Abou-Donia MB, Dieckert JW: Gossypol: uncoupling of respiratory chain and oxidative phosphorylation . Life Sci 1974, 14 (10):1955-1963. Tso WW, Lee CS: Gossypol uncoupling of respiratory chain and oxidative phosphorylation in ejaculated boar spermatozoa . Contraception 1982, 25 (6):649-655. Gadelha IC, Fonseca NB, Oloris SC, Melo MM, Soto-Blanco B: Gossypol toxicity from cottonseed products . ScientificWorldJournal 2014, 2014 :231635. Dong Q, Xing W, Fu F, Liu Z, Wang J, Liang X, Zhou X, Yang Q, Zhang W, Gao F et al : Tetrahydroxystilbene Glucoside Inhibits Excessive Autophagy and Improves Microvascular Endothelial Dysfunction in Prehypertensive Spontaneously Hypertensive Rats . Am J Chin Med 2016, 44 (7):1393-1412. Liu Y, Wang YL, He SW, Chen MH, Zhang Z, Fu XP, Fu BB, Liao BQ, Lin YH, Qi ZQ et al : Protective effects of resveratrol against mancozeb induced apoptosis damage in mouse oocytes . Oncotarget 2017, 8 (4):6233-6245. Chang CH, Lee CY, Lu CC, Tsai FJ, Hsu YM, Tsao JW, Juan YN, Chiu HY, Yang JS, Wang CC: Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling . Int J Oncol 2017, 50 (3):873-882. Rong M, Wang S, Ma L, Kuang M, Jin Y, Zhou D, Fang D, Xu S, Wang Y: Progress of research on the extraction and application of cotton phenol . Chinese cotton 2019, 46 (03):1-6+10. Wang GQX, Wang Y: Preparation of Cotton Phenol and its use . China Oil & Grease 2002(03):58-59. Additional Declarations No competing interests reported. Supplementary Files CAREchecklist.pdf Cite Share Download PDF Status: Published Journal Publication published 19 May, 2025 Read the published version in BMC Urology → Version 1 posted Editorial decision: Accepted 28 Apr, 2025 Reviews received at journal 26 Apr, 2025 Reviewers agreed at journal 18 Apr, 2025 Reviews received at journal 15 Apr, 2025 Reviewers agreed at journal 15 Apr, 2025 Reviewers agreed at journal 14 Apr, 2025 Reviews received at journal 14 Apr, 2025 Reviewers agreed at journal 14 Apr, 2025 Reviewers invited by journal 14 Apr, 2025 Submission checks completed at journal 12 Apr, 2025 First submitted to journal 11 Apr, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5693104","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Case Report","associatedPublications":[],"authors":[{"id":442900846,"identity":"2d54f163-74b1-486a-a4ab-18a20ddcbb5c","order_by":0,"name":"Ming Zhao","email":"","orcid":"","institution":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","correspondingAuthor":false,"prefix":"","firstName":"Ming","middleName":"","lastName":"Zhao","suffix":""},{"id":442900847,"identity":"04032380-63ea-42fc-918c-839122e23daf","order_by":1,"name":"Dongyang Jiang","email":"","orcid":"","institution":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","correspondingAuthor":false,"prefix":"","firstName":"Dongyang","middleName":"","lastName":"Jiang","suffix":""},{"id":442900848,"identity":"57fea423-1102-4f86-9273-4c951fbbd604","order_by":2,"name":"Pengcheng Zhou","email":"","orcid":"","institution":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","correspondingAuthor":false,"prefix":"","firstName":"Pengcheng","middleName":"","lastName":"Zhou","suffix":""},{"id":442900849,"identity":"bf5395c0-c51e-4854-b817-42a0f89b1693","order_by":3,"name":"Yinglan Liang","email":"","orcid":"","institution":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","correspondingAuthor":false,"prefix":"","firstName":"Yinglan","middleName":"","lastName":"Liang","suffix":""},{"id":442900851,"identity":"52f564a8-be19-468e-89cf-bd4b890b00bf","order_by":4,"name":"Jian Liu","email":"","orcid":"","institution":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","correspondingAuthor":false,"prefix":"","firstName":"Jian","middleName":"","lastName":"Liu","suffix":""},{"id":442900853,"identity":"e94fa163-e57d-4e97-bc02-95862cbfc077","order_by":5,"name":"Hongwei Su","email":"","orcid":"","institution":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","correspondingAuthor":false,"prefix":"","firstName":"Hongwei","middleName":"","lastName":"Su","suffix":""},{"id":442900855,"identity":"6d995d04-5ecb-400f-8e87-b38f4473be85","order_by":6,"name":"Qiongdan Hu","email":"","orcid":"","institution":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","correspondingAuthor":false,"prefix":"","firstName":"Qiongdan","middleName":"","lastName":"Hu","suffix":""},{"id":442900857,"identity":"356b928a-c702-48ef-ab35-435e8f243754","order_by":7,"name":"Qiong Zhang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAv0lEQVRIiWNgGAWjYBACA4nEB0DKRo6fmfnwAyK1JCQAqTRjyXa2NAPitPAcAGk5lLjhPI+CBHFa2BsSH/zccSBx82EeBgOGGptowlqYGZINe8/cMd52mPfAA4ZjabkNRGhJk+Bteya77TBfggFjw2GitKT//Nt2mHFzM4+BBJFaWNKYedsOK25gJl4L22Fp2bY0Y4nDwEBOIMYv9s3MjR/ftgGjsv/w4QcfamwIa0EFCaQpHwWjYBSMglGACwAA+Z8+a/JopyAAAAAASUVORK5CYII=","orcid":"","institution":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","correspondingAuthor":true,"prefix":"","firstName":"Qiong","middleName":"","lastName":"Zhang","suffix":""}],"badges":[],"createdAt":"2024-12-22 09:53:06","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-5693104/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5693104/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12894-025-01807-6","type":"published","date":"2025-05-19T15:58:37+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":80787183,"identity":"e39c120c-7118-434c-822e-a7101e29b416","added_by":"auto","created_at":"2025-04-17 06:05:18","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":26793,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eIF image of renal biopsy. \u003c/strong\u003eIgG (-), IgA (-), IgM (+), C3 (-), C1q (-), Fib (-), ALB (-).\u003c/p\u003e","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-5693104/v1/ec8c135f3b30fdb679e0964e.png"},{"id":80785354,"identity":"39f6f779-8e32-4954-8e1b-28bbed182a48","added_by":"auto","created_at":"2025-04-17 05:40:44","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":418455,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eH\u0026amp;E stain image of renal biopsy.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA (×4.0, H\u0026amp;E stain) The renal tissue appears light purple. B (×40.0, H\u0026amp;E stain) Granular degeneration of renal tubular epithelial cells (blue arrow). The cells are swollen, with loose and pale - stained cytoplasm, and occasional protein casts are seen (brown arrow).C (×40.0, H\u0026amp;E stain) Interstitial granulomas with formation of multinucleated giant cells are visible (black arrow). D (×40.0, H\u0026amp;E stain) A relatively large - scale atrophy of renal tubules is observed (orange arrow), with narrowed lumens. A large number of renal tubules have necrosed and disappeared, replaced by proliferated connective tissue (green arrow). Inflammatory cell infiltration mainly composed of lymphocytes is visible (purple arrow).\u003c/p\u003e","description":"","filename":"floatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-5693104/v1/b9e140a3717b6f68bcd03419.png"},{"id":80785351,"identity":"2dd31b00-dd56-4342-96c5-0707e16481ed","added_by":"auto","created_at":"2025-04-17 05:40:44","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":202920,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMasson stain image of renal biopsy.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA (×4.0, Masson stain): Collagen fibers are stained blue, while other tissues are stained red. B (×40.0, Masson stain): Partial fibrosis in the renal tissue can be observed. The proliferation of collagen fibers is visible in the renal interstitium (yellow arrow), and the proliferated collagen fibers are distributed in a reticular pattern.\u003c/p\u003e","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-5693104/v1/3d7845e62ea88a0287173ec9.png"},{"id":80785362,"identity":"ac916a14-b68f-4e23-a384-9031309e0185","added_by":"auto","created_at":"2025-04-17 05:40:45","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":140672,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePAS stain image of renal biopsy.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA (×4.0, PAS stain): The renal tissue as a whole appears light purple. B (×40.0, PAS stain): A small amount of brush - border shedding is visible in the renal tubules (black arrow). There is no obvious glycogen deposition in the epithelial cells, and the cell nuclei are light blue. Serous substances with a purplish - red color are occasionally seen in the renal tubules (red arrow).\u003c/p\u003e","description":"","filename":"floatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-5693104/v1/73513a9dddd8dbfdb581583c.png"},{"id":80785348,"identity":"e5e7eeef-c846-47a2-bde1-95f3efc36468","added_by":"auto","created_at":"2025-04-17 05:40:44","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":213570,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMethenamine silver stain image of renal biopsy.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA (×4.0, Methenamine silver stain): The basement membrane of the glomerular capsule, the basement membrane of renal tubular epithelium, and the reticular fibers all appear black, with a red background. B (×40.0, Methenamine silver stain): Marked thickening (red arrow) and intensified staining of the renal tubular basement membranes are observable.\u003c/p\u003e","description":"","filename":"floatimage5.png","url":"https://assets-eu.researchsquare.com/files/rs-5693104/v1/a8aa37a42a178ac62e7a3404.png"},{"id":80785368,"identity":"6eb921c0-9712-4fe3-95a5-77fb0534b42e","added_by":"auto","created_at":"2025-04-17 05:40:45","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":74826,"visible":true,"origin":"","legend":"\u003cp\u003eFluctuation of creatinine throughout the course of disease\u003c/p\u003e","description":"","filename":"floatimage6.png","url":"https://assets-eu.researchsquare.com/files/rs-5693104/v1/f4575281265eaf5be7f95a19.png"},{"id":83460702,"identity":"2d1f6938-379d-4817-8ca0-45e83e3a2272","added_by":"auto","created_at":"2025-05-26 16:13:40","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":3283602,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5693104/v1/cc684fc4-9a83-4414-a6a4-28cd0f9bc835.pdf"},{"id":80785349,"identity":"932c3c64-bbca-4ee5-926a-1baa41d95974","added_by":"auto","created_at":"2025-04-17 05:40:44","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":151414,"visible":true,"origin":"","legend":"","description":"","filename":"CAREchecklist.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5693104/v1/a22cbe4c39402715c18c3af3.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"A case report of acute interstitial nephritis caused by cotton phenol","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAcute interstitial nephritis (AIN) is a tubulointerstitial renal disease characterised by acute inflammation and oedema of the renal interstitium, accompanied by impairment of renal tubular function. It is also known as acute tubulo-interstitial nephritis. The term AIN was first proposed by Councilman in 1898 during the autopsy of a group of patients with diphtheria and scarlet fever. The incidence of AIN varies considerably between different countries and regions. A review of the literature on renal biopsy cases indicates that AIN accounts for 1\u0026ndash;2% of cases in many countries[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. In patients who have had renal biopsies for acute kidney injury(AKI), AIN accounts for 15\u0026ndash;27% of cases[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. The most common causes of AIN can be categorised into four groups: exogenous compounds such as drugs, infections, autoimmune disorders, and idiopathic causes (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e), with drugs being the most prevalent[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. All causes of AIN may present with nonspecific signs and symptoms of acute renal insufficiency, including acute or subacute nausea, vomiting, discomfort, oliguria and haematuria.\u003c/p\u003e \u003cp\u003eWe present a case of severe AKI triggered by exposure to cotton phenol. Percutaneous nephron puncture biopsy confirmed that the patient's renal failure was caused by AIN. The objective of this case report is to emphasise the role of cotton phenol as a rare cause of AIN. Through in-depth analysis of this case, we aim to enhance the understanding of AIN and provide guidance for the diagnosis and management of similar cases in the future.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eCauses of acute interstitial nephritis[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"2\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCause of disease\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eInstance\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eExogenous compounds such as drugs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAntibiotics (Penicillins, Cephalosporins, Quinolones, Sulfonamides, Macrolides),\u003c/p\u003e \u003cp\u003eanti-retrovirals (Abacavir, Acyclovir, Atazanavir, Azythromycin, Foscarnet, Indinavir, Interferon-alpha),\u003c/p\u003e \u003cp\u003enon-steroidal anti-inflammatory drugs (Celecoxib, Rofecoxib, Diclofenac),\u003c/p\u003e \u003cp\u003ediuretics (Chlorothiazide, Hydrochlorothiazide), anticonvulsants (Carbamazepine, Diazepam, Lamotrigine, Levetiracetam, Phenobarbital, Phenytoin, Valproic acid),\u003c/p\u003e \u003cp\u003eproton pump inhibitors (Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, Rabeprazole),\u003c/p\u003e \u003cp\u003eH2 receptor blockers (Cimetidine, Famotidine, Ranitidine),\u003c/p\u003e \u003cp\u003eherbs(traditional Chinese herbal medicines containing triptolide, ephedrine, aristolochic acid)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eInfections\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBacteria, viruses, leptospira, mycobacterium tuberculosis, mycoplasma, chlamydia.\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAutoimmune disease\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSystemic lupus erythematosus, nodular disease, Sj\u0026ouml;gren\u0026rsquo;s syndrome.\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIdiopathic\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAnti-renal tubular basement membrane disease, interstitial nephritis\u0026ndash;uveitis syndrome.\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e"},{"header":"Case report","content":"\u003cp\u003eA 56-year-old male patient was admitted to hospital with recurrent nausea, accompanied by elevated blood creatinine for 2 months. Two months ago, he was assessed in the local hospital for nausea and found to have renal insufficiency: urea 15.8 mmol/L, blood creatinine 4.95 mg/dL, and uric acid 9.66 mg/dL. Routine urinalysis revealed urinary protein 1+. Urological ultrasound revealed: right kidney size 9.1 cm × 4.9 cm, left kidney size 10.2 cm × 5.7 cm, and right kidney stone. After treatment with uric acid control (sodium bicarbonate) and volume management in the local hospital, there was no relief of the above symptoms, and he was transferred to our hospital for further consultation.\u003c/p\u003e\n\u003cp\u003eHe had no antecedent history of kidney-related disorders. During annual routine physical examinations, no evidence of impaired renal function was identified. Additionally, the patient denied a history of other specific diseases, including hypertension, diabetes mellitus, hepatitis, and tuberculosis. His vital signs were all normal at the time of admission, with no positive findings. The blood routine examination results indicated the presence of mild anemia along with a potential inflammatory state. The serum creatinine level was elevated to 7.21 mg/dL. In the urinalysis, 2 + urinary occult blood was detected; the levels of urinary α₁-microglobulin and urinary microalbumin were abnormally elevated; the result of the 24-hour urinary protein quantification was normal. No abnormalities were found in either the liver function tests or the immunological assays. The chest computed tomography (CT) scan demonstrated scattered inflammatory foci in the lungs and multiple nodules, for which the probability of them being inflammatory nodules was considered to be high. The detailed examination results are presented as follows:\u003c/p\u003e\n\u003cdiv\u003e\n \u003ctable id=\"Tab2\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv\u003eTable 2\u003c/div\u003e\n \u003cdiv\u003e\n \u003cp\u003ePatient's preliminary laboratory results\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003ccolgroup cols=\"4\"\u003e\u003c/colgroup\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eIndex\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eResults\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eNormal Reference Range for Adult Males\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eRoutine blood tests\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ered blood cell count (×10\u003csup\u003e12\u003c/sup\u003e/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e3.89\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e4.0 ~ 5.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ehaemoglobin (g/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e113\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e120 ~ 160\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ewhite blood cell count (×10⁹/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e4.77\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e4 ~ 10\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eneutrophil absolute count (×10⁹/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e3.48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e2 ~ 7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003elymphocyte absolute count (×10⁹/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.71\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.8 ~ 4.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ehigh-sensitivity C-reactive protein (mg/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e9.41\u003csup\u003e✝\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026lt; 3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eplatelet count (×10⁹/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e274\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e100 ~ 300\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eerythrocyte sedimentation rate (mm/h)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e57\u003csup\u003e✝\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0 ~ 20\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eLiver function\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ealbumin (g/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e38.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e35 ~ 55\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eglobulin (g/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e31.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e20 ~ 35\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003etotal bilirubin (µmol/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e3.4 ~ 17.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003easpartate aminotransferase (U/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026lt; 40\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ealanine aminotransferase (U/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026lt; 40\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eKidney function\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eblood urea nitrogen (mmol/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e21.6\u003csup\u003e✝\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e2.9 ~ 7.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eblood creatinine (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e7.21\u003csup\u003e✝\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.6 ~ 1.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003euric acid (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e9.87\u003csup\u003e✝\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e3.5 ~ 7.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eElectrolytes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eK (mmol/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e4.18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e3.5 ~ 5.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNa (mmol/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e140\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e135 ~ 145\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eCl (mmol/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e103\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e96 ~ 106\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eCa (mmol/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e2.29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e2.25 ~ 2.58\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePi (mmol/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e1.45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.97 ~ 1.61\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eMg (mmol/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.7 ~ 1.10\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eRoutine urinalysis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eurine potein\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eleukocyturi\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eoccult blood in urine\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e2+\u003csup\u003e✝\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eParathyroid hormone (pg/mL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e20.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e15 ~ 65\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eurine α₁-microglobulin (mg/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e227\u003csup\u003e✝\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0 ~ 15\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eurine microalbumin (mg/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e90.8\u003csup\u003e✝\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026lt; 30\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003e24-hour urine output (L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e1.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003e24-hour urine protein quantification (mg/24H)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e129.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026lt; 150\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eAutoantibody spectrum\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003enRNP/Sm antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSm antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eRo-52 antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSS-B antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eScl-70 antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePM-Scl antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eJo-1 antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eCENP-B antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePCNA antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003edsDNA antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNucleosome antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eHistone\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eRibosomal P protein\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAMA M2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eanti-MPO antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eanti-PR3 antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eanti-GBM antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSS-A antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eANA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eAntistreptolysin O (IU/ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026lt; 25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0 ~ 200\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eRheumatoid Factor\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026lt; 20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0 ~ 20\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eComplement\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eC3 (g/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e1.09\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.7 ~ 1.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eC4 (g/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.1 ~ 0.4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eHepatitis B Five-item Test\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eHBsAg (IU/ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0 ~ 0.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAnti-HBs (mIU/ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.89\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0 ~ 10\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eHBeAg (IU/ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0 ~ 0.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAnti-HBe (PEI U/ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0 ~ 0.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAnti-HBc (PEI U/ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0 ~ 0.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eHepatitis C Virus Antibody Test (S/CO)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026lt; 1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eHIV Antibody Test (S/CO)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026lt; 1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eTP Antibody Test (S/CO)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026lt; 1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003e*: the corresponding value is below the lower limit of the normal reference range; ✝: the corresponding value is above the upper limit of the normal reference range.\u003c/p\u003e\n\u003cp\u003eChest CT: (1) Nodules in the posterior segment of the upper lobe of the right lung with peripheral inflammatory changes, consider the possibility of infectious lesions, suggest follow-up after treatment; scattered inflammatory changes in both lungs. (2) Multiple solid nodular shadows in both lungs, inflammatory nodules? (3)Multiple mediastinal lymph nodes showing partial calcification; localised pleural calcification in the left lung apex.\u003c/p\u003e\n\u003cp\u003eRenal puncture biopsy: granulomatous interstitial nephritis (Fig. 1–5).\u003c/p\u003e\n\u003cp\u003eNo immune complex deposition was observed.\u003c/p\u003e\n\u003cdiv id=\"Sec3\"\u003e\n \u003ch2\u003e3. Treatment and follow-up\u003c/h2\u003e\n \u003cp\u003e\u003cstrong\u003e3.1. Days 1–11 after admission\u003c/strong\u003e: The patient was admitted with a clear AKI, and potential pulmonary infection, and was immediately treated with anti-infection (piperacillin sodium), volume management, maintenance of a stable internal environment, and dietary guidance. We continued to test his vital signs, as well as any fluctuations of his high-sensitivity C-reactive protein (hs-CRP), electrolytes and renal function. The patient's renal function showed a trend of continued progression, and renal puncture biopsy was perfected on day 7 after admission, and the hs-CRP was reduced to normal (2.27 mg/L). Chest CT showed that the pulmonary nodules were reduced.\u003cbr\u003e \u003cstrong\u003e3.2. From day 11 after admission to discharge\u003c/strong\u003e: The pathology report of renal biopsy was returned on day 11 after admission. After integrating the patient's auxiliary examination and medical history, we finally diagnosed the patient with cotton-phenol-induced AIN. At that time, the patient's blood creatinine level was already as high as 7.88 mg/dL. He continued to follow the treatment plan for 3 days, and on day 14, blood creatinine level was rechecked as 7.95 mg/dL. In accordance with the patient's wishes, renal replacement therapy was not carried out at that time. So we decided to use glucocorticoids, and after 14 days of intravenous glucocorticoids (40mg/day), the blood creatinine level gradually decreased to 3.30 mg/dL. Symptoms such as nausea gradually disappeared and his appetite gradually improved. The patient was discharged from hospital when his condition improved gradually (Fig. 6).\u003cbr\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e3.3 Post-discharge follow-up\u003c/strong\u003e: The patient was discharged on regular glucocorticosteroids (40 mg po daily) and blood creatinine was 2.04 mg/dL 1 month after discharge.\u003c/p\u003e\n\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe patient was admitted to the hospital with a definite diagnosis of AKI, but the primary etiology remained unclear. We conducted tests for anti-myeloperoxidase (MPO) antibody, anti-proteinase 3 (PR3) antibody, antinuclear antibody (ANA), double-stranded DNA (dsDNA), and complement levels, all of which showed no abnormalities. Therefore, we ruled out the diagnoses of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, systemic lupus erythematosus nephritis, IgG4-related diseases, and hypocomplementemic AIN. Tests for anti-Ro/SSA and anti-La/SSB antibodies and rheumatoid factor (RF) were also performed, and the results did not support the diagnosis of Sj\u0026ouml;gren's syndrome. The results of streptococcal serology, as well as serology for hepatitis B and C, were all negative, which was inconsistent with virus-associated nephritis. Although the chest CT scan and hs-CRP indicated the presence of a pulmonary infection, the patient had no respiratory symptoms such as fever or chills, nor any systemic symptoms. The white blood cell count did not increase abnormally. Further improvement of sputum culture did not detect any bacterial or fungal infections. Moreover, after 7 days of anti-infective treatment, a repeated chest CT scan showed that the pulmonary nodules had decreased in size compared with the previous one, and the hs-CRP had dropped to the normal level. In summary, the patient's infection was under control, but the serum creatinine level did not decrease, and the renal function did not improve. Therefore, infectious interstitial nephritis was not considered. All the above common infectious, autoimmune, and idiopathic etiologies were excluded. Further improvement of renal puncture biopsy confirmed that the patient had granulomatous interstitial nephritis. We considered the possibility of AIN caused by sarcoidosis or Mycobacterium tuberculosis infection. We further improved the relevant examinations. Although the patient's T-Cell-based Interferon-Gamma Release Assay (TB-IGRA) result was positive and the chest CT scan also suggested infectious changes, the acid-fast staining of urine sediment and the test for Mycobacterium tuberculosis were both negative. The infectious changes in the lungs did not conform to the typical manifestations of pulmonary tuberculosis. At the same time, the patient had no previous history of tuberculosis, and there were no typical symptoms such as hemoptysis, chest pain, hectic fever, night sweats, or weight loss during hospitalization. In conclusion, the possibility of AIN caused by tuberculosis was extremely low. Although the chest CT scan of the patient suggested multiple nodules, they were considered to be infectious nodules. Meanwhile, the patient's serum calcium level was normal, and no typical manifestations of sarcoidosis were found during physical examination. Therefore, AIN caused by sarcoidosis was also not considered. We carefully inquired about the patient's medical history again. The patient recalled that he had changed his job 5 months ago. His new job mainly involved automotive repair and maintenance. In his daily work, the lubricating oil he used was crude cottonseed oil that he pressed from cottonseeds by himself. This crude cottonseed oil contains a large amount of gossypol[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. He came into bare-handed contact with the crude cottonseed oil every day. Moreover, his working environment had poor ventilation, and he worked about 6 hours a day. During work, he neither wore a mask nor gloves. In a follow-up visit after the patient was discharged from the hospital, he stated that his colleagues in the same position as him also had the same impaired renal function. Finally, we diagnosed the patient as having a granulomatous AIN caused by large amounts of cotton phenol exposure. we clarified the final aetiology during a follow-up visit after the patient was discharged, when he stated that his workmates in the same position as him had the same impaired renal function. It has been shown experimentally that cotton phenol can cause renal damage in mice, as demonstrated by diffuse thylakoid cell hyperplasia, increased thylakoid stroma, adhesion to the wall layer of the renal capsule, marked reduction or even disappearance of the renal capsule lumen, disruption of the structural texture, and morphological abnormalities[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eCotton phenol is a polyphenolic compound, with the chemical formula C\u003csub\u003e30\u003c/sub\u003eH\u003csub\u003e30\u003c/sub\u003eO\u003csub\u003e8\u003c/sub\u003e, that occurs naturally in the cotton plant, which can enhance the plant resistance to pests. In terms of medical applications, cotton phenol and its derivatives show a wide range of therapeutic potential. In addition to its properties against some viruses and bacteria[\u003cspan additionalcitationids=\"CR7 CR8 CR9 CR10 CR11\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e], cotton phenol has been investigated as a potential drug for the treatment of a wide range of malignancies such as leukaemia, lymphoma, colon cancer, breast cancer, leiomyosarcoma and prostate cancer[\u003cspan additionalcitationids=\"CR14 CR15 CR16 CR17 CR18 CR19 CR20 CR21 CR22 CR23 CR24 CR25\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. Its mechanism of action involves inhibition of tumour cell proliferation and induction of apoptosis, and these properties have made cotton phenol the subject of much attention in the field of anticancer therapy. In addition, cotton phenol has shown significant value in the treatment of gynaecological conditions, such as uterine fibroids, endometriosis and uterine bleeding. It was introduced into clinical practice in China in the 1970s and continues to be explored for its potential application in the treatment of gynaecological diseases[\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. Although the application of cotton phenol is promising, its reproductive toxicity has limited its widespread clinical use. Therefore, researchers are endeavouring to find and develop safer and more effective derivatives to further expand its applications.\u003c/p\u003e \u003cp\u003eCotton phenol can also cause toxic effects in animals, mainly through the Browning or Meladic reaction with amino acids, which reduces the absorption and utilisation of amino acids, or by interfering with the activity of enzymes in the electron transport chain of mitochondria (especially dehydrogenases and oxidoreductases) or by directly damaging the mitochondrial membrane. It also affects the mitochondrial membrane potential, leading to mitochondrial dysfunction, thus affecting cellular energy metabolism and inducing toxicity[\u003cspan additionalcitationids=\"CR28\" citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]. Cotton phenol can also lead to a decrease in the number of leukocytes and major lymphocytes, thus affecting immunity[\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. Cotton phenol has been reported to cause toxicity in a variety of animals such as cattle, sheep, pigs ,dogs and chickens, which may result in congestion and oedema of internal organs, liver and kidney damage, or cardiac damage[\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eAIN is an AKI characterised by acute inflammation and oedema of the renal interstitium, accompanied by acute tubular dysfunction. Clinical diagnosis of AIN can usually be made on the basis of the typical history, clinical manifestations and laboratory tests, but renal puncture biopsy is the gold standard for the diagnosis. The usual treatments for AIN are: (1) removal of causative factors, such as, stopping related drugs, and treating primary infection; (2) systemic supportive therapy; and (3) immunosuppressive therapy, including glucocorticoids and immunosuppressive drugs. Timely diagnosis and treatment can avoid disease progression, and some patients can fully recover renal function, whereas others may progress to chronic kidney disease. In conclusion, the causative factors, disease duration, degree of renal function impairment, degree of interstitial fibrosis, and the timeliness and appropriateness of the treatment all affect the prognosis of AIN.\u003c/p\u003e \u003cp\u003eThe use of glucocorticoids in the treatment of AIN has been controversial. The best evidence in support of glucocorticoid therapy comes from a retrospective multicentre study in Spain, which included 61 patients with biopsy-proven AIN; 52 of whom received glucocorticoid therapy. Despite the small sample size of the control group, with only nine patients who did not receive glucocorticoids, the results showed a positive impact of glucocorticoids on the recovery of renal function and shedding of dialysis at 18-months' follow-up[\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]. Although there have been several small studies with similar results to this study[\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e], not all of them have supported the efficacy of glucocorticoids. For example, a retrospective study in 2004 in the USA found that glucocorticoids did not show any therapeutic advantage in 60 patients with biopsy-confirmed drug-induced AIN[\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e]. Some negative studies have suggested that the ineffectiveness of glucocorticoid therapy may be related to the inclusion of patients with more severe disease and patients with AIN induced by nonsteroidal anti-inflammatory drugs (where glucocorticoids may be ineffective). However, in the present case, the patient's renal function recovered rapidly after glucocorticoids were activated.\u003c/p\u003e \u003cp\u003eThis case reminds physicians to consider the possibility of AIN in any diagnosis of unexplained AKI, and the need for timely medical history review and consideration of the patient's environmental exposures when the aetiological diagnosis is more difficult, in order to avoid missed or misdiagnosis, which may delay treatment and affect prognosis. At present, cotton phenol and its derivatives find extensive applications. For instance, they are utilized in the manufacture of anti-fertility drugs, for the prevention and management of pests and diseases in crops[\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e], and serve as antioxidants in the rubber industry, polyethylene industry, polypropylene industry, as well as in rocket fuel and so on[\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e]. This reminds physicians to consider it as a potential nephrotoxicant when they see patients engaged in the relevant industries.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 112px;\"\u003e\n \u003cp\u003eAIN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 442px;\"\u003e\n \u003cp\u003eacute interstitial nephritis\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 112px;\"\u003e\n \u003cp\u003eAKI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 442px;\"\u003e\n \u003cp\u003eacute kidney injury\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 112px;\"\u003e\n \u003cp\u003eANA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 442px;\"\u003e\n \u003cp\u003eantinuclear antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 112px;\"\u003e\n \u003cp\u003eANCA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 442px;\"\u003e\n \u003cp\u003eantineutrophil cytoplasmic antibody\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 112px;\"\u003e\n \u003cp\u003eANCA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 442px;\"\u003e\n \u003cp\u003eantineutrophil cytoplasmic antibodies\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 112px;\"\u003e\n \u003cp\u003eCT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 442px;\"\u003e\n \u003cp\u003ecomputed tomography\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 112px;\"\u003e\n \u003cp\u003edsDNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 442px;\"\u003e\n \u003cp\u003edouble-stranded DNA\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 112px;\"\u003e\n \u003cp\u003ehs-CRP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 442px;\"\u003e\n \u003cp\u003ehigh-sensitivity C-reactive protein\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 112px;\"\u003e\n \u003cp\u003eMPO\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 442px;\"\u003e\n \u003cp\u003emyeloperoxidase\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 112px;\"\u003e\n \u003cp\u003ePR3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 442px;\"\u003e\n \u003cp\u003eproteinase 3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis case report was in adherence with the Declaration of Helsinki and approved by the Ethics Committee of The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, approval number KY2023020-FS01. The authors declared that written informed consent was obtained from the patient for publication of this case report and accompanying images.\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe article has been read by the patient himself and agreed to be published in \u0026apos; BMC Urology\u0026rsquo;. Our patient gave written informed consent for their personal or clinical details along with any identifying images to be published in this study. (The specific written informed consent can be seen in the relevant documents uploaded.) \u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials \u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets used during the current study are available from the corresponding author on reasonable request. \u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e \u003c/p\u003e\n\u003cp\u003eThe authors declare no competing interests. \u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding \u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis research was supported by \u0026lsquo;Luzhou Municipal People\u0026apos;s Government-Southwest Medical University Science and Technology Strategic Cooperation Project\u0026rsquo;, \u0026lsquo;Sichuan Science and Technology Program\u0026rsquo;, \u0026lsquo;Sichuan Administration of Traditional Chinese Medicine\u0026rsquo; and \u0026lsquo;Southwest Medical University - Southwest Medical University affiliated Hospital of Traditional Chinese Medicine joint project\u0026rsquo;.\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions \u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMZ, DJ, PZ, and JL contributed to patient diagnosis, management, and clinical data analysis. \u003c/p\u003e\n\u003cp\u003eMZ, HS, YL and QH contributed to the patient\u0026rsquo;s pathological diagnosis and took and edited pathological pictures. \u003c/p\u003e\n\u003cp\u003eMZ and DJ wrote the manuscript draft and contributed to data analysis, and interpretation. \u003c/p\u003e\n\u003cp\u003eQZ made final changes to the interpretation of the pathology images in the manuscript and to the content of the manuscript.\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAcknowledgements \u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eZhang Q, Chen N: \u003cstrong\u003eThe etiology and pathogenesis of acute interstitial nephritis and progress in its diagnosis and treatment\u003c/strong\u003e. \u003cem\u003eChinese Journal of Practical Internal Medicine \u003c/em\u003e2006(06):476-478.\u003c/li\u003e\n\u003cli\u003ePraga M, Gonz\u0026aacute;lez E: \u003cstrong\u003eAcute interstitial nephritis\u003c/strong\u003e. \u003cem\u003eKidney Int \u003c/em\u003e2010, \u003cstrong\u003e77\u003c/strong\u003e(11):956-961.\u003c/li\u003e\n\u003cli\u003eRaghavan R, Eknoyan G: \u003cstrong\u003eAcute interstitial nephritis - a reappraisal and update\u003c/strong\u003e. \u003cem\u003eClin Nephrol \u003c/em\u003e2014, \u003cstrong\u003e82\u003c/strong\u003e(3):149-162.\u003c/li\u003e\n\u003cli\u003eQian SZ, Wang ZG: \u003cstrong\u003eGossypol: a potential antifertility agent for males\u003c/strong\u003e. \u003cem\u003eAnnu Rev Pharmacol Toxicol \u003c/em\u003e1984, \u003cstrong\u003e24\u003c/strong\u003e:329-360.\u003c/li\u003e\n\u003cli\u003eWang H, Piao Z, Ma H, Cao L, Liu J, Wu J: \u003cstrong\u003e[Short-term exposure to gossypol causes reversible reproductive toxicity and nephrotoxicity in mice]\u003c/strong\u003e. \u003cem\u003eNan Fang Yi Ke Da Xue Xue Bao \u003c/em\u003e2023, \u003cstrong\u003e43\u003c/strong\u003e(2):251-256.\u003c/li\u003e\n\u003cli\u003ePolsky B, Segal SJ, Baron PA, Gold JW, Ueno H, Armstrong D: \u003cstrong\u003eInactivation of human immunodeficiency virus in vitro by gossypol\u003c/strong\u003e. \u003cem\u003eContraception \u003c/em\u003e1989, \u003cstrong\u003e39\u003c/strong\u003e(6):579-587.\u003c/li\u003e\n\u003cli\u003eYang J, Zhang F, Li J, Chen G, Wu S, Ouyang W, Pan W, Yu R, Yang J, Tien P: \u003cstrong\u003eSynthesis and antiviral activities of novel gossypol derivatives\u003c/strong\u003e. \u003cem\u003eBioorg Med Chem Lett \u003c/em\u003e2012, \u003cstrong\u003e22\u003c/strong\u003e(3):1415-1420.\u003c/li\u003e\n\u003cli\u003eYang J, Chen G, Li LL, Pan W, Zhang F, Yang J, Wu S, Tien P: \u003cstrong\u003eSynthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism\u003c/strong\u003e. \u003cem\u003eBioorg Med Chem Lett \u003c/em\u003e2013, \u003cstrong\u003e23\u003c/strong\u003e(9):2619-2623.\u003c/li\u003e\n\u003cli\u003eMargalith P: \u003cstrong\u003eInhibitory effect of gossypol on microorganisms\u003c/strong\u003e. \u003cem\u003eAppl Microbiol \u003c/em\u003e1967, \u003cstrong\u003e15\u003c/strong\u003e(4):952-953.\u003c/li\u003e\n\u003cli\u003eYildirim-Aksoy M, Lim C, Dowd MK, Wan PJ, Klesius PH, Shoemaker C: \u003cstrong\u003eIn vitro inhibitory effect of gossypol from gossypol-acetic acid, and (+)- and (-)-isomers of gossypol on the growth of Edwardsiella ictaluri\u003c/strong\u003e. \u003cem\u003eJ Appl Microbiol \u003c/em\u003e2004, \u003cstrong\u003e97\u003c/strong\u003e(1):87-92.\u003c/li\u003e\n\u003cli\u003eTurco E, Vizzuso C, Franceschini S, Ragazzi A, Stefanini FM: \u003cstrong\u003eThe in vitro effect of gossypol and its interaction with salts on conidial germination and viability of Fusarium oxysporum sp. vasinfectum isolates\u003c/strong\u003e. \u003cem\u003eJ Appl Microbiol \u003c/em\u003e2007, \u003cstrong\u003e103\u003c/strong\u003e(6):2370-2381.\u003c/li\u003e\n\u003cli\u003eArinbasarova AY, Medentsev AG, Krupyanko VI: \u003cstrong\u003eGossypol Inhibits Electron Transport and Stimulates ROS Generation in Yarrowia lipolytica Mitochondria\u003c/strong\u003e. \u003cem\u003eOpen Biochem J \u003c/em\u003e2012, \u003cstrong\u003e6\u003c/strong\u003e:11-15.\u003c/li\u003e\n\u003cli\u003eBalakrishnan K, Wierda WG, Keating MJ, Gandhi V: \u003cstrong\u003eGossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells\u003c/strong\u003e. \u003cem\u003eBlood \u003c/em\u003e2008, \u003cstrong\u003e112\u003c/strong\u003e(5):1971-1980.\u003c/li\u003e\n\u003cli\u003eJohnson PW: \u003cstrong\u003eNew targets for lymphoma treatment\u003c/strong\u003e. \u003cem\u003eAnn Oncol \u003c/em\u003e2008, \u003cstrong\u003e19 Suppl 4\u003c/strong\u003e:iv56-59.\u003c/li\u003e\n\u003cli\u003eWang X, Wang J, Wong SC, Chow LS, Nicholls JM, Wong YC, Liu Y, Kwong DL, Sham JS, Tsa SW: \u003cstrong\u003eCytotoxic effect of gossypol on colon carcinoma cells\u003c/strong\u003e. \u003cem\u003eLife Sci \u003c/em\u003e2000, \u003cstrong\u003e67\u003c/strong\u003e(22):2663-2671.\u003c/li\u003e\n\u003cli\u003eVan Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K, Borgen P, Gollub M, Bacotti D, Yao TJ\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eOral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial\u003c/strong\u003e. \u003cem\u003eBreast Cancer Res Treat \u003c/em\u003e2001, \u003cstrong\u003e66\u003c/strong\u003e(3):239-248.\u003c/li\u003e\n\u003cli\u003eYe W, Chang HL, Wang LS, Huang YW, Shu S, Dowd MK, Wan PJ, Sugimoto Y, Lin YC: \u003cstrong\u003eModulation of multidrug resistance gene expression in human breast cancer cells by (-)-gossypol-enriched cottonseed oil\u003c/strong\u003e. \u003cem\u003eAnticancer Res \u003c/em\u003e2007, \u003cstrong\u003e27\u003c/strong\u003e(1a):107-116.\u003c/li\u003e\n\u003cli\u003eHan ML, Wang YF, Tang MY, Ge QS, Zhou LF, Zhu PD, Sun YT: \u003cstrong\u003eGossypol in the treatment of endometriosis and uterine myoma\u003c/strong\u003e. \u003cem\u003eContrib Gynecol Obstet \u003c/em\u003e1987, \u003cstrong\u003e16\u003c/strong\u003e:268-270.\u003c/li\u003e\n\u003cli\u003eJiang J, Slivova V, Jedinak A, Sliva D: \u003cstrong\u003eGossypol inhibits growth, invasiveness, and angiogenesis in human prostate cancer cells by modulating NF-\u0026kappa;B/AP-1 dependent- and independent-signaling\u003c/strong\u003e. \u003cem\u003eClin Exp Metastasis \u003c/em\u003e2012, \u003cstrong\u003e29\u003c/strong\u003e(2):165-178.\u003c/li\u003e\n\u003cli\u003eTuszynski GP, Cossu G: \u003cstrong\u003eDifferential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines\u003c/strong\u003e. \u003cem\u003eCancer Res \u003c/em\u003e1984, \u003cstrong\u003e44\u003c/strong\u003e(2):768-771.\u003c/li\u003e\n\u003cli\u003eWu YW, Chik CL, Knazek RA: \u003cstrong\u003eAn in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenocortical carcinoma\u003c/strong\u003e. \u003cem\u003eCancer Res \u003c/em\u003e1989, \u003cstrong\u003e49\u003c/strong\u003e(14):3754-3758.\u003c/li\u003e\n\u003cli\u003eBadawy SZ, Souid AK, Cuenca V, Montalto N, Shue F: \u003cstrong\u003eGossypol inhibits proliferation of endometrioma cells in culture\u003c/strong\u003e. \u003cem\u003eAsian J Androl \u003c/em\u003e2007, \u003cstrong\u003e9\u003c/strong\u003e(3):388-393.\u003c/li\u003e\n\u003cli\u003eKo CH, Shen SC, Yang LY, Lin CW, Chen YC: \u003cstrong\u003eGossypol reduction of tumor growth through ROS-dependent mitochondria pathway in human colorectal carcinoma cells\u003c/strong\u003e. \u003cem\u003eInt J Cancer \u003c/em\u003e2007, \u003cstrong\u003e121\u003c/strong\u003e(8):1670-1679.\u003c/li\u003e\n\u003cli\u003eChien CC, Ko CH, Shen SC, Yang LY, Chen YC: \u003cstrong\u003eThe role of COX-2/PGE2 in gossypol-induced apoptosis of colorectal carcinoma cells\u003c/strong\u003e. \u003cem\u003eJ Cell Physiol \u003c/em\u003e2012, \u003cstrong\u003e227\u003c/strong\u003e(8):3128-3137.\u003c/li\u003e\n\u003cli\u003eHsiao WT, Tsai MD, Jow GM, Tien LT, Lee YJ: \u003cstrong\u003eInvolvement of Smac, p53, and caspase pathways in induction of apoptosis by gossypol in human retinoblastoma cells\u003c/strong\u003e. \u003cem\u003eMol Vis \u003c/em\u003e2012, \u003cstrong\u003e18\u003c/strong\u003e:2033-2042.\u003c/li\u003e\n\u003cli\u003eWong FY, Liem N, Xie C, Yan FL, Wong WC, Wang L, Yong WP: \u003cstrong\u003eCombination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression\u003c/strong\u003e. \u003cem\u003ePLoS One \u003c/em\u003e2012, \u003cstrong\u003e7\u003c/strong\u003e(12):e50786.\u003c/li\u003e\n\u003cli\u003eMeksongsee LA, Clawson AJ, Smith FH: \u003cstrong\u003eThe in vivo effect of gossypol on cytochrome oxidase, succinoxidase, and succinic dehydrogenase in animal tissues\u003c/strong\u003e. \u003cem\u003eJ Agric Food Chem \u003c/em\u003e1970, \u003cstrong\u003e18\u003c/strong\u003e(5):917-920.\u003c/li\u003e\n\u003cli\u003eAbou-Donia MB, Dieckert JW: \u003cstrong\u003eGossypol: uncoupling of respiratory chain and oxidative phosphorylation\u003c/strong\u003e. \u003cem\u003eLife Sci \u003c/em\u003e1974, \u003cstrong\u003e14\u003c/strong\u003e(10):1955-1963.\u003c/li\u003e\n\u003cli\u003eTso WW, Lee CS: \u003cstrong\u003eGossypol uncoupling of respiratory chain and oxidative phosphorylation in ejaculated boar spermatozoa\u003c/strong\u003e. \u003cem\u003eContraception \u003c/em\u003e1982, \u003cstrong\u003e25\u003c/strong\u003e(6):649-655.\u003c/li\u003e\n\u003cli\u003eGadelha IC, Fonseca NB, Oloris SC, Melo MM, Soto-Blanco B: \u003cstrong\u003eGossypol toxicity from cottonseed products\u003c/strong\u003e. \u003cem\u003eScientificWorldJournal \u003c/em\u003e2014, \u003cstrong\u003e2014\u003c/strong\u003e:231635.\u003c/li\u003e\n\u003cli\u003eDong Q, Xing W, Fu F, Liu Z, Wang J, Liang X, Zhou X, Yang Q, Zhang W, Gao F\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eTetrahydroxystilbene Glucoside Inhibits Excessive Autophagy and Improves Microvascular Endothelial Dysfunction in Prehypertensive Spontaneously Hypertensive Rats\u003c/strong\u003e. \u003cem\u003eAm J Chin Med \u003c/em\u003e2016, \u003cstrong\u003e44\u003c/strong\u003e(7):1393-1412.\u003c/li\u003e\n\u003cli\u003eLiu Y, Wang YL, He SW, Chen MH, Zhang Z, Fu XP, Fu BB, Liao BQ, Lin YH, Qi ZQ\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eProtective effects of resveratrol against mancozeb induced apoptosis damage in mouse oocytes\u003c/strong\u003e. \u003cem\u003eOncotarget \u003c/em\u003e2017, \u003cstrong\u003e8\u003c/strong\u003e(4):6233-6245.\u003c/li\u003e\n\u003cli\u003eChang CH, Lee CY, Lu CC, Tsai FJ, Hsu YM, Tsao JW, Juan YN, Chiu HY, Yang JS, Wang CC: \u003cstrong\u003eResveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling\u003c/strong\u003e. \u003cem\u003eInt J Oncol \u003c/em\u003e2017, \u003cstrong\u003e50\u003c/strong\u003e(3):873-882.\u003c/li\u003e\n\u003cli\u003eRong M, Wang S, Ma L, Kuang M, Jin Y, Zhou D, Fang D, Xu S, Wang Y: \u003cstrong\u003eProgress of research on the extraction and application of cotton phenol\u003c/strong\u003e. \u003cem\u003eChinese cotton \u003c/em\u003e2019, \u003cstrong\u003e46\u003c/strong\u003e(03):1-6+10.\u003c/li\u003e\n\u003cli\u003eWang GQX, Wang Y: \u003cstrong\u003ePreparation of Cotton Phenol and its use\u003c/strong\u003e. \u003cem\u003eChina Oil \u0026amp; Grease \u003c/em\u003e2002(03):58-59.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-urology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"buro","sideBox":"Learn more about [BMC Urology](http://bmcurol.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/buro/default.aspx","title":"BMC Urology","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"case report, cotton phenol, acute interstitial nephritis, glucocorticosteroid","lastPublishedDoi":"10.21203/rs.3.rs-5693104/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5693104/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBACKGROUND\u003c/h2\u003e \u003cp\u003eCotton phenol is a yellowish-brown polyphenol hydroxybinaphthyl aldehyde compound mainly found in the roots, stems, leaves and seeds of cotton; a plant of the mallow family that has been widely used in the study of antifertility and antitumor drugs. However, there has been no report of serious renal injuries caused by cotton phenol. We report a case of granulomatous acute interstitial nephritis caused by exposure to large amounts of cotton phenol.\u003c/p\u003e\u003ch2\u003eCASE DESCRIPTION\u003c/h2\u003e \u003cp\u003eThe patient was a 56-year-old male with nausea and a blood creatinine level of 4.95 mg/dL 2 month prior to admission. He was admitted to the hospital with worsening nausea, blood creatinine level of 7.21 mg/dL, and a renal puncture biopsy suggesting granulomatous acute interstitial nephritis. The patient had no specific past medical history. Laboratory tests (double-stranded DNA, antineutrophil cytoplasmic antibody, extractable nuclear antigen, rheumatoid subunit, serum and urine protein electrophoresis, complement levels, immunoglobulin subclasses, streptococcal serology, and hepatitis B and C serology were negative, normal or undetectable. Follow-up history revealed that the patient receives large quantities of cotton phenol at work. The diagnosis was granulomatous acute interstitial nephritis induced by exposure to cotton phenol. Treatment was volume management, maintenance of a stable internal environment, and glucocorticoid activation. Blood creatinine level gradually decreased to 1.86 mg/dL after 3 month and his condition improved.\u003c/p\u003e\u003ch2\u003eCONCLUSIONS\u003c/h2\u003e \u003cp\u003ePhysicians encountering patients with acute interstitial nephritis of uncertain etiology are obligated to conduct a prompt and comprehensive history review. Special attention should be given to cotton phenol and its derivatives as they may potentially act as nephrotoxic agents. The application of glucocorticoids in the treatment of acute interstitial nephritis remains a subject of debate. However, in this particular case, the patient exhibited a rapid restoration of renal function following the administration of glucocorticoids.\u003c/p\u003e","manuscriptTitle":"A case report of acute interstitial nephritis caused by cotton phenol","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-04-17 05:40:38","doi":"10.21203/rs.3.rs-5693104/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Accepted","date":"2025-04-28T14:46:20+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-04-26T21:37:42+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"11332723311853127051493149229480193714","date":"2025-04-18T14:42:42+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-04-15T10:01:18+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"304309549925822240954817132894905477857","date":"2025-04-15T09:25:34+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"70229967265687035254419006862227474486","date":"2025-04-14T20:17:52+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-04-14T14:52:30+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"286940261158492524547039247102471839743","date":"2025-04-14T14:26:34+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-04-14T13:44:40+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-04-12T16:42:22+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Urology","date":"2025-04-11T07:12:49+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-urology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"buro","sideBox":"Learn more about [BMC Urology](http://bmcurol.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/buro/default.aspx","title":"BMC Urology","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"8755c432-8447-450b-a3e8-c0fb06199cfe","owner":[],"postedDate":"April 17th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-05-26T16:11:01+00:00","versionOfRecord":{"articleIdentity":"rs-5693104","link":"https://doi.org/10.1186/s12894-025-01807-6","journal":{"identity":"bmc-urology","isVorOnly":false,"title":"BMC Urology"},"publishedOn":"2025-05-19 15:58:37","publishedOnDateReadable":"May 19th, 2025"},"versionCreatedAt":"2025-04-17 05:40:38","video":"","vorDoi":"10.1186/s12894-025-01807-6","vorDoiUrl":"https://doi.org/10.1186/s12894-025-01807-6","workflowStages":[]},"version":"v1","identity":"rs-5693104","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5693104","identity":"rs-5693104","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}